Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avastin, Paclitaxel, and Cisplatin in Advanced Ovarian Cancer
NCT00511992Phase 2Completed
- Sponsor
- University of Oklahoma
- Start
- Jul 2007
- Primary completion
- Aug 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in ovarian carcinoma, primary peritoneal carcinoma (PPC) and ovarian carcinosarcoma (OCS), sponsored by University of Oklahoma. Primary endpoint: Number of Patients Able to Complete 6 Cycles of Treatment at 2 years. Started Jul 2007; status: completed.
02
Drugs
bevacizumab
03
Conditions
ovarian carcinomaprimary peritoneal carcinoma (PPC)ovarian carcinosarcoma (OCS)
Beyond the preview
Go deeper on NCT00511992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00511992.